Altium Capital Management LP Eiger Bio Pharmaceuticals, Inc. Transaction History

Altium Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	BUY	$3.84 - $9.74 $687,360 - $1.74 Million	179,000 Added 68.58%	440,000 $3.65 Million
Q4 2021 Feb 14, 2022	BUY	$5.12 - $8.19 $325,120 - $520,064	63,500 Added 32.15%	261,000 $1.36 Million
Q3 2021 Nov 17, 2021	SELL	$6.68 - $9.1 $424,180 - $577,850	-63,500 Reduced 24.33%	197,500 $1.32 Million
Q3 2021 Nov 15, 2021	BUY	$6.68 - $9.1 $424,180 - $577,850	63,500 Added 32.15%	261,000 $2.12 Million
Q4 2020 Feb 16, 2021	BUY	$7.98 - $12.29 $1.58 Million - $2.43 Million	197,500 New	197,500 $2.43 Million

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $418M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Altium Capital Management LP with notifications on news.